Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan

Size: px
Start display at page:

Download "Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan"

Transcription

1 Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review of the New Drugs with monographs: 1. Velphoro (sucroferric oxyhydroxide) chewable tablets phosphate binder indicated for lowering phosphate levels in patients with chronic kidney disease on dialysis. [PDL class- Electrolyte Depleters. Non-prefer.] ( PDL page 17) 2. Zohydro ER (hydrocodone bitartrate) capsule. C-II medication indicated for severe pain requiring around-the-clock management [PDL class narcotic analgesics. Non-prefer.] (PDL page 1) 3. Luzu 1% (luliconazole) cream indicated for treatment of interdigital tinea pedis, tinea cruruis and tinea corporis. [PDL class-topcial Antifungals. Non-prefer.] ( PDL page 3) 4. Anoro Ellipta (umeclidinium bromide/vilanterol) inhaler Once daily inhaler for COPD (only). [PDL class- COPD Agents Non-prefer.] (PDL page 5) 5. Hetlioz (tasimelteon) capsule indicated for non-24-hour sleep-wake disorder. [ PDL class Sedative/Hypnotics. Non-prefer.] (PDL page 13) 6. Xartemis XR (oxycodone/acetaminophen) capsules indicated for acute pain severe enough to require opiod treatment and for which alternative treatment options are inadequate. [PDL Class Narcotic analgesics. Non-prefer.] (PDL page 1) 7. Orenitram ER (treprostinil diolamine) tablet indicated for pulmonary arterial hypertension WHO Group 1 to improve exercise capacity. [Not a PDL class.] 8. Otezla (apremilast) tablet indicated for the treatment of adults with active psoriatic arthritis. [PDL Class Biologic Immunomodulators. Non-prefer.] (PDL page 17) Recommendation of workgroup to add to criteria for approval for both Otezla and Xeljanz : the request come from, or documentation of consultation with, a rheumatologist. Line Extensions: None 1

2 Review of the Gastrointestinal Drug Class (PDL Page 15): 1. Nausea Agents: Oral a. Make Sancuso non-preferred. 2. Substance P Receptor Agonist a. Make Emend packs (only, not tablets) non-preferred. 3. Pancreatic Enzymes a. Make all products except generic pancrealipase non-preferred. 4. Progestins for Cachexia 5. Proton Pump Inhibitors a. Add Nexium OTC to posted PDL as preferred. 6. Ulcerative Colitis. Review of the Diabetes Drug Class ( PDL List pages 13-15): 1. Amylin Analogs: 2. Incretin Mimetics. 3. Insulin, Basal 4. Insulin, Rapid Acting 5. Insulin, Mixes. 6. Insulin, Traditional 2

3 Diabetes continued: 7. Oral Hypoglycemics Alpha Glucosidase Inhibitors 8. Oral Hyoglycemics Biguanides a. Make Metformin ER (generic for Fortamet) non-preferred. Keep Metformin ER Glucophage XR generic version - as preferred. 9. Oral Hypoglycemics - Combinations a. Make Duetact non-preferred. b. Make pioglitazone/metformin non-preferred c. Make Prandimet non-preferred. 10. Oral Hypoglycemics Dopamine Receptor Agonits 11. Oral Hypoglycemics DPP4 Inhibitors a. Drugs in this class are clinically equivalent. Department may choose preferred drug based on price. 12. Oral Hypoglycemics - Meglitinides a. Make repaglinide generic preferred. 13. Oral Hypoglycemics 2 nd Generation 14. Oral Hypoglycemics SGLT2 Inhibitors a. Make Farxiga preferred. i. Note: this class already has a step edit that requires a metformin containing product in the claims history in order for the claim to pay without Prior Authorization 15. Oral Hypoglycemics - Thiazolidineiones Miscellaneous Drug Class (PDL Pages 17 19): Anticoagulants 3

4 Miscellaneous Drug Class continued: Biologic Immunomodulators b. Make new drug Otezla non-preferred. Add requirement to both Otezla and Xeljanz : request from, or documentation of consultation with, a rheumatologist. BPH Agents a. Add Cardura and generic to PDL. b. Make Cardura and Cardura XL non-preferred. Combination Benzoyl Peroxide/Clindamycin a. Make generic clindamycin/benzoyl peroxide products (both) non-preferred Electrolyte Depleters a. Make Renvela powder non-preferred. b. Make sevelamer capsules non-preferred. Fibromyalgia Agents a. Add duloxetine generic to posted PDL as preferred. Growth Hormones a. Make Genotropin products non-preferred. Hematopoietic Agents Osteoporosis Agents: Bisphosphonates a. Make alendronate oral solution non-preferred. Osteoporosis Agents: Other Osteoporosis Agents: SERMS a. Add generic raloxifene as preferred. b. Make Evista brand non-preferred. Platelet Aggregation Inhibitors 4

5 Skeletal Muscle Relaxants a. Make methocarbamol non-preferred. Ask the DUR Board to look at prolonged and/or repeated use of drugs in this class. Committee suggests consideration of a future limit to a 30 day supply no more than 3 times in 12 months. Topical Immunomodulators a. Make Protopic non-preferred. Urinary Tract Antispasmodics Topical Steroids: Low potency (New PDL Class) Recommend future reviews in December. i. Hydrocortisone acetate cream and ointment ii. Hydrocortisone cream, gel, lotion, solution and ointment iii. Aclometasone dipropionate ointment and cream i. Hydrocortisone-aloe ointment and gel ii. Neosporin iii. Salpicin iv. Hydrocortiosn/mineral oil/petrolatum ointment v. Verdeso vi. Texacort vii. Hydrocortisone acetate/urea viii. Capex shampoo ix. Desonide ointment, cream and lotion x. Desonate gel xi. Derma-smooth-FS xii. Fluocinolone 0.01% oil xiii. Desowen lotion xiv. Aqua glycolic HC xv. Pediaderm TA 5

6 Topical Steroids: Medium potency (New PDL Class) i. Mometasone furoate ointment, cream and solution ii. Hydrocortisone butyrate ceam, ointment and solution iii. Fluticasone propionate cream and ointment i. Dermatop cream and ointment ii. Pandel iii. Elocon ointment, cream and solution iv. Curivate cream and lotion v. Luxiq vi. Colderm vii. Synalar solution, cream and ointment viii. Flucinolone acetonide cream, lotion and solution ix. Synalar TS kit x. Prednicarbate ointment xi. Hydrocortisone valerate cream and ointment xii. Locid lipocream xiii. Momexin xiv. Cordran tape xv. Betamethasone valerate foam Topical Steroids: High potency (New PDL Class) i. Triamcinolone acetonide cream, ointment and lotion ii. Fluocinonide cream, ointment and gel iii. Betamethasone valerate ointment and cream i. Betamethasone dipropionate/propylene glycol cream, lotion and ointment ii. Diprolene AF cream and ointment iii. Fluocinonide emollient and solution iv. Betamethasone valerate lotion v. Bethamethasone dipropionate cream, gel and ointment vi. Halog ointment and cream vii. Vanos viii. Desoximetasone cream and gel ix. Kenalog aerosol x. Diprolene ointment xi. Trianex ointment xii. Diflorasone diacetate cream and ointment xiii. Topicort cream, spray and ointment xiv. Amcinonide lotion and ointment 6

7 19 Topical Steroids: Very High potency (New PDL Class) i. Clobetasol propionate solution, cream, ointment and gel ii. Halobetasol propionate ointment and cream i. Clobex lotion, spray and shampoo ii. Clobetasol emollient and lotion iii. Temovate ointment iv. Clobex shampoo v. Olux vi. Ultravate X PAC cream and ointment vii. Halonate viii. Olux-E ix. Apexicon E x. Clobetasol propionate foam 20. Public Comments: Ndidi Yaucher, Pharm.D., MBA: Novartis Pharmaceuticals, Gilenya George Anderson, Ph.D., Astra Zeneca, Symbicort Kirsty Kerin, Ph.D., Vanda Pharmaceuticals, Hetlioz Jay Mehta, Pharm.D., Biogen, Plegridy Next Meeting: Tuesday, December 9, 2014 Next Drug Categories: Analgesics & CNS 7

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Comparison of representative topical corticosteroid preparations (classified according to the US system) Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics

More information

Pharmacy Benefit Determination Policy

Pharmacy Benefit Determination Policy Policy Subject: Atopic Dermatitis Agents Policy Number: SHS PBD18 Category: Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS PPO ASO s:

More information

Drug Class Literature Scan: Topical Steroids

Drug Class Literature Scan: Topical Steroids Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Michigan Pharmacy and Therapeutics Committee September 11, Minutes

Michigan Pharmacy and Therapeutics Committee September 11, Minutes Michigan Pharmacy and Therapeutics Committee September 11, 2018 Minutes Attendees: Vickie Tutag Lehr, Brian Peltz, Jayne Courts, Rony Foumia, Andrew Mac, Andrew Adair, Margo Farber, David Neff, Brad Uren

More information

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Comparison of representative topical corticosteroid preparations (classified according to the US system) Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)

More information

Effective for all members on August 1, 2017

Effective for all members on August 1, 2017 August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017

More information

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

2015 Step Therapy Prior Authorization Medical Necessity Guidelines Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154

More information

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017

More information

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

The safety and effectiveness of Dupixent in pediatric patients have not been established (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent

More information

Connecticut Medicaid P&T Meeting Minutes December 2, 2010

Connecticut Medicaid P&T Meeting Minutes December 2, 2010 Connecticut Medicaid P&T Meeting Minutes December 2, 2010 The meeting started at 6:34 pm Attendance Present Members: Carl Sherter, MD Peggy Manning Memoli, Pharm D Eric Einstein, MD Charles Thompson, MD

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Enstilar, Sernivo, Taclonex) Reference Number: CP.CPA.255 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end

More information

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.

More information

2018 Step Therapy (ST) Criteria

2018 Step Therapy (ST) Criteria 2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a

More information

Step Therapy Criteria 2019

Step Therapy Criteria 2019 Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD

More information

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018

More information

Pharmacologic Treatment of Atopic Dermatitis

Pharmacologic Treatment of Atopic Dermatitis J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc

More information

ALLERGIC RHINITIS-NASAL

ALLERGIC RHINITIS-NASAL ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step

More information

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Step Therapy Medications

Step Therapy Medications Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on

More information

ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018

ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018 Step Therapy Requirements Effective April 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone

More information

ANTIEMETICS STEP. Step Therapy Requirements Effective April 1, 2019

ANTIEMETICS STEP. Step Therapy Requirements Effective April 1, 2019 Step Therapy Requirements Effective April 1, 2019 ANTIEMETICS STEP Sancuso 3.1 mg/24 hour transdermal patch Zuplenz 4 mg oral soluble film Zuplenz 8 mg oral soluble film COVERAGE OF CERTAIN BRAND NAME

More information

ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018

ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018 Step Therapy Requirements Effective June 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone

More information

High-Cost Drug Exclusions

High-Cost Drug Exclusions PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at

More information

DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG

More information

ALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017

ALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone 15 mg tablet alogliptin 12.5 mg-pioglitazone

More information

Pharmacy and Therapeutics Committee

Pharmacy and Therapeutics Committee Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee December 13, 2016 Minutes Attendees: Dr. Tutag Lehr, Andrew Mac, James Miller, Brian Peltz, Dr. Anthony Ognjan, Dr.

More information

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so

More information

Dupixent (dupilumab)

Dupixent (dupilumab) Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee

Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee June 14, 2016 Minutes Final Attendee: Dr. Tutag Lehr, Andrew Mac, James Miller, Brian Peltz, Dr. Anthony Ognjan, Dr.

More information

Topical Immunomodulators

Topical Immunomodulators Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Topical Immunomodulators Clinical Edit Information Included in this Document Topical Immunomodulators Elidel and Protopic 0.03%

More information

BlueLink TPA FlexRx Updates

BlueLink TPA FlexRx Updates BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%

More information

Kentucky Department for Medicaid Services. Drug Review Options

Kentucky Department for Medicaid Services. Drug Review Options Kentucky Department for Medicaid Services Drug Review Options The following chart lists the agenda items scheduled and the options submitted for review at the March 18, 2010 meeting of the Pharmacy and

More information

Drug Formulary Update, April 2017 Commercial and State Programs

Drug Formulary Update, April 2017 Commercial and State Programs Drug Formulary Update, April 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,

More information

2015 Medicare Step Therapy Criteria. Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014

2015 Medicare Step Therapy Criteria. Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014 2015 Medicare Step Therapy Criteria Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014 1 Table of Contents AMITIZA, LINZESS... 3 ANTIDEPRESSANTS - Viibryd / Pexeva / Pristiq / Desvenlafaxine...

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Technology Appraisals and Guidance Information Services Static List Review (SLR) report Title and TA publication number of static topic: Final decision:

More information

High-Cost Drug Exclusions

High-Cost Drug Exclusions Pharmacy Services High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at

More information

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date: Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

2017 Formulary Changes Year to Date

2017 Formulary Changes Year to Date 2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or

More information

Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)

Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals) This report highlights all changes (additions, deletions and removals) to the CVS Caremark Prescribing Guide Standard Control. ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Estring (estradiol)

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE February 18, 2015 SUBJECT EFFECTIVE DATE January 21, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Drug List (PDL) Update January 21, 2015 Pharmacy Services Vincent D. Gordon, Deputy

More information

Secretary for Health and Family Services Selections for Preferred Products

Secretary for Health and Family Services Selections for Preferred Products Secretary for Health and Family Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Secretary for Health and Family Services based

More information

84:00. Skin and Mucous Membrane Agents. 84:00 Skin and Mucous Membrane Agents

84:00. Skin and Mucous Membrane Agents. 84:00 Skin and Mucous Membrane Agents Skin and Mucous Membrane Agents Skin and Mucous Membrane Agents COMPOUND PRESCRIPTION 00000999119 00000999112 COMPOUND - RETINOIC ACID (TRETINOIN) () MISCELLANEOUS COMPOUND To be used when the compound

More information

Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018

Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 Texas Vendor Drug Program Formulary Drug Index File Layout Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 The Vendor Drug Program provides a weekly update of resource data available for download

More information

PHARMA-MEDIC SERVICES INC. POLICY MANUAL

PHARMA-MEDIC SERVICES INC. POLICY MANUAL PHARMA-MEDIC SERVICES INC. POLICY MANUAL SUBJECT: INDEX: P.5.a.iii Automatic-Therapeutic Substitution DATE: June 1/2011 REVISED: March 2, 2015., Feb 2017. PROCEDURE: 1. Long term care homes use the Manitoba

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Quarterly pharmacy formulary change notice Provider update Summary: Effective August 1, 2018, the preferred formulary changes detailed in the table below will apply to District of Columbia Healthy Families

More information

Your prescription benefit updates Formulary Updates - Effective January 1, 2019

Your prescription benefit updates Formulary Updates - Effective January 1, 2019 Your prescription benefit updates Formulary Updates - Effective January 1, 2019 Medications are grouped by the conditions they treat. Each medication is placed in a tier that shows the amount you will

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet

More information

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates April 2018 TRADE NAME (generic name) or generic name Brand/Generic Description of Change abacavir sulfate soln 20 mg/ml (base equiv) Generic

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Dupixent) Reference Number: CP.PHAR.336 Effective Date: 05.01.17 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder

More information

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved. Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.

More information

Advanced Control Formulary Change Summary Report Effective

Advanced Control Formulary Change Summary Report Effective This report highlights all changes (additions, deletions, and removals) to the CVS Caremark Advanced Control Formulary ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Cystagon (cysteamine bitartrate)

More information

Texas Vendor Drug Program. Formulary Delimited File Layout. April 26, 2017

Texas Vendor Drug Program. Formulary Delimited File Layout. April 26, 2017 Texas Vendor Drug Program Formulary Delimited File Layout April 26, 2017 The Vendor Drug Program provides a weekly update of resource data available for download from txvendordrug.com/resources/downloads.

More information

Literature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy

Literature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

2014 Medicare Step Therapy Criteria. Last Modified: Last Submitted to CMS:

2014 Medicare Step Therapy Criteria. Last Modified: Last Submitted to CMS: 2014 Medicare Step Therapy Criteria Last Modified: 09.30.2014 Last Submitted to CMS: 09.02.2014 1 Table of Contents AMITIZA, LINZESS... 3 ANTIDEPRESSANTS - Viibryd / Pexeva / Pristiq / Desvenlafaxine...

More information

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations Kentucky Department for Medicaid Services Pharmacy and March 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Provider update Quarterly pharmacy formulary change notice Summary: The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018, Pharmacy and Therapeutics Committee

More information

Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria

Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time

More information

79 C. Michael Davenport Blvd. Suite A Frankfort, KY August 5, Dear Kentucky Medicaid Provider:

79 C. Michael Davenport Blvd. Suite A Frankfort, KY August 5, Dear Kentucky Medicaid Provider: 79 C. Michael Davenport Blvd. Suite A Frankfort, KY 40601 August 5, 2010 Dear Kentucky Medicaid Provider: Please be advised that the Department for Medicaid Services is making changes to the Kentucky Medicaid

More information

Managing and Minimizing Flare-ups in Atopic Dermatitis

Managing and Minimizing Flare-ups in Atopic Dermatitis Managing and Minimizing Flare-ups in Atopic Dermatitis Importance of the skin barrier & how commonly used drugs are impacting it Dr. Benjamin Barankin, MD FRCPC Medical Director & Founder of Toronto Dermatology

More information

Pharmacy and Therapeutics Committee

Pharmacy and Therapeutics Committee Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee September 12, 2017 Minutes - Final Attendees: Vickie Tutag Lehr, Andrew Mac, James Miller, Brian Peltz, Anthony Ognjan,

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Provider Bulletin October 2018 Quarterly pharmacy formulary change notice The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. The changes listed in the table

More information

Quarterly pharmacy formulary change

Quarterly pharmacy formulary change Medi-Cal Managed Care L. A. Care Major Risk Medical Insurance Program Provider Bulletin The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018 Pharmacy and

More information

High-Cost Drug Exclusions

High-Cost Drug Exclusions PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at our second quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October

More information

OTC PRODUCTS. 4 Gama Benzene HCL 0.1% + Proflavine Hermisulphate 0.1% + Cetrimide 0.45% Cream

OTC PRODUCTS. 4 Gama Benzene HCL 0.1% + Proflavine Hermisulphate 0.1% + Cetrimide 0.45% Cream OTC PRODUCTS SR. No. COMPOSITION Allantoin 0.2% + Dimethicone 1% + Urea 10% + Propylene Glycol 5% + Glyserine 5% + 1 Light Liquid Paraffin 8% Cream (FOOT CREAM) 2 Aquous Cream 3 Cetrimide 0.5% + Chlorhexidine

More information

Quarterly Pharmacy Formulary Change Notice

Quarterly Pharmacy Formulary Change Notice MEDICAID PROVIDER BULLETIN February 26, 2015 Quarterly Pharmacy Formulary Change Notice Summary of Change: The formulary changes listed in the table below were reviewed and approved at our September 24,

More information

Pharmaceutical and Therapeutics Committee

Pharmaceutical and Therapeutics Committee Earl Ray Tomblin Governor STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES Bureau for Medical Services Pharmacy Services 350 Capitol Street Room 251 Charleston, West Virginia 25301-3706

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice MEDICAID PROVIDER BULLETIN October 2018 The formulary changes listed in the table below were reviewed and approved at the second-quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October

More information

2019 PacificSource Health Plans Step Therapy Criteria. Last Modified: 02/22/2019 (All criteria reviewed at least once per year)

2019 PacificSource Health Plans Step Therapy Criteria. Last Modified: 02/22/2019 (All criteria reviewed at least once per year) 2019 PacificSource Health Plans Step Therapy Criteria Last Modified: 02/22/2019 (All criteria reviewed at least once per year) Table of Contents ACTICLATE... 3 AMITIZA/LINZESS... 4 ANTIDIABETICS Farxiga,

More information

Kentucky Department for Medicaid Services Drug Review and Options for Consideration

Kentucky Department for Medicaid Services Drug Review and Options for Consideration Drug Review and The following table lists the Agenda items scheduled, as well as the, to be presented and reviewed at the March 16, 2017 meeting of the Pharmacy and Therapeutics Advisory Committee. Single

More information

San Francisco Health Plan (SFHP)

San Francisco Health Plan (SFHP) San Francisco Health Plan (SFHP) The following changes to SFHP formulary and prior authorization criteria were reviewed and approved by the SFHP Pharmacy and Therapeutics (P&T) Committee on 07/18/2018.

More information

2017 Step Therapy (ST) Criteria

2017 Step Therapy (ST) Criteria 2017 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a

More information

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION Added Prior Authorization 7/1/17 CORLANOR 5 MG TABLET Added Prior Authorization 7/1/17 CORLANOR 7.5 MG TABLET Added Prior Authorization 7/1/17

More information

15 minute eczema consultation

15 minute eczema consultation THERAPY WORKSHOP 15 minute eczema consultation History Current treatments Examination Treatment Plan Written action plan Soap substitute/bath oil Antiseptic baths Emollients Topical steroids Other treatments

More information

Michigan Pharmacy and Therapeutics Committee

Michigan Pharmacy and Therapeutics Committee Michigan Pharmacy and Therapeutics Committee June 14, 2016 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: I. Introductions II. Conflict of Interest Statement III. Approval of the Agenda IV.

More information

Pharmacy Updates Summary

Pharmacy Updates Summary All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 10/28/2014 Effective date: 11/15/2014 Therapeutic Classes reviewed: Pulmonary arterial hypertension

More information

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT NOVEMBER 30, 2010

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT NOVEMBER 30, 2010 IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201056 NOVEMBER 30, 2010 Changes to the Preferred Drug List Changes to the Preferred Drug List (PDL) were made at the November 19, 2010, Drug Utilization

More information

WellCare s South Carolina Preferred Drug List Update

WellCare s South Carolina Preferred Drug List Update WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/21/2017.

More information

2018 Step Therapy FID 18088

2018 Step Therapy FID 18088 2018 Step Therapy FID 18088 Step Therapy ANTIDEPRESSANTS, SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS LEON 2018 Desvenlafaxine Er Fetzima Fetzima Titration Pack Khedezla Paxil SUSP Pristiq Trintellix

More information

Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria

Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria ALBENDAZOLE Mercy Care ALBENZA TABLET 200 MG ORAL Refer to PA Guideline for approval criteria 1 BRIMONIDINE-TIMOLOL COMBIGAN SOLUTION 0.2-0.5 % OPHTHALMIC Requires use of separate ingredients for at least

More information

Updates to your prescription benefits

Updates to your prescription benefits Updates to your prescription benefits Effective Jan. 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE SUBJECT EFFECTIVE DATE January 20, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See Below BY Drug List (PDL) Update January 20, 2016 Pharmacy Services Leesa M. Allen, Deputy Secretary Office of

More information

Drug List exclusions for Blue Cross commercial plans

Drug List exclusions for Blue Cross commercial plans Drug List exclusions for Blue Cross commercial plans The drugs shown below aren t covered on the commercial Blue Cross Blue Shield of Michigan drug lists. In most cases, if you fill a prescription for

More information

DECISION PAPER DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS August 2013

DECISION PAPER DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS August 2013 DECISION PAPER DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS August 2013 I. UNIFORM FORMULARY DRUG CLASS REVIEWS A. Corticosteroid Immune Modulators (Topical Steroids) Background

More information

Updates to your prescription benefits

Updates to your prescription benefits Updates to your prescription benefits Effective January 1, 2019 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill

More information

Calgary Long Term Care Formulary

Calgary Long Term Care Formulary Page 1 of 10 Calgary Long Term Care Formulary Pharmacy & Therapeutics November 2018 Highlights https://www.albertahealthservices.ca/info/page4071.aspx Page 2 of 10 Contents November 2018... 3 Formulary

More information

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MAY 29, 2012

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MAY 29, 2012 IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201218 MAY 29, 2012 Changes to the Preferred Drug List Changes to the Preferred Drug List (PDL) were made at the May 18, 2012, Drug Utilization Review (DUR)

More information

Updates to your prescription benefits

Updates to your prescription benefits Updates to your prescription benefits Effective Jan. 1, 2019 Traditional Three-Tier PDL Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount

More information